エストロゲン受容体モジュレーターの世界市場レポート 2025年

エストロゲン受容体モジュレーター市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4%で236億8,000万米ドルに成長します。予測期間中に予想される成長は、次世代SERMのパイプラインの拡大、がん研究開発への投資の増加、ホルモン感受性がんの有病率の上昇、個別化医療への幅広い採用、新規エストロゲン受容体モジュレーターの承認が期待されることに起因しています。この時期の主な動向としては、選択的エストロゲン受容体分解薬（SERD）の発展、組織選択的モジュレーターの開発、併用療法アプローチの革新、バイオマーカーに基づく薬剤ターゲティングの進展、安全性プロファイルが強化された経口SERMの創出などが挙げられます。

乳がんの有病率の増加は、今後のエストロゲン受容体モジュレーター市場の成長を牽引すると予想されます。乳がんは、乳房の異常細胞が制御不能に増殖して腫瘍を形成し、周囲の組織に浸潤したり、体の他の部位に転移したりする疾患です。乳がん患者の増加は、より多くの女性が出産を遅らせ、ホルモンレベルを変化させ、生涯のエストロゲン暴露を増加させ、それによってがんリスクを上昇させることに関連しています。エストロゲン受容体モジュレーターは、がん細胞に対するエストロゲンの作用を阻害または変化させ、その増殖を遅らせ、病気の進行や再発のリスクを減らすことによって、乳がんの管理に重要な役割を果たします。例えば、2025年2月、米国を拠点とする政府間組織である国連は、2022年、乳がんが全世界で約230万人の新規患者と67万人の死亡者を占めたと報告しました。2050年までには、新規患者数は38％増加し、年間死亡者数は68％増加すると世界的に予測されており、この疾病の影響が増大していることが強調されています。したがって、乳がんの有病率の上昇がエストロゲン受容体モジュレーター市場を前進させています。

エストロゲン受容体モジュレーター市場の主要企業は、エストロゲンベースの更年期ホルモン療法などの革新的な治療法の開発に注力しており、ほてりなどの更年期症状を効果的に緩和すると同時に、ホルモン関連のがんや心血管系の問題に関連するリスクを最小限に抑えています。エストロゲンベースの更年期ホルモン療法は、更年期に関連する症状を緩和するために、エストロゲンを単独で、あるいはプロゲスチンと組み合わせて投与するものです。例えば、2023年6月、米国の製薬・バイオテクノロジー企業であるファイザー社は、DUAVEE（共役エストロゲン／バゼドキシフェン）をパッケージをリニューアルして再販しました。このホルモン療法は、子宮のある閉経後女性を対象とし、共役エストロゲンと選択的エストロゲン受容体モジュレーターであるバゼドキシフェンを組み合わせたものです。子宮内膜肥厚のリスクを低下させることで、従来のエストロゲン・プロゲスチン併用療法に代わる治療法を提供します。DUAVEEは経口錠剤として1日1回投与され、症状管理に必要な最短期間の投与が勧められます。一般的な副作用は、筋肉の痙攣、吐き気、胃の不快感などです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のエストロゲン受容体モジュレーター：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエストロゲン受容体モジュレーター市場：成長率分析
• 世界のエストロゲン受容体モジュレーター市場の実績：規模と成長、2019年～2024年
• 世界のエストロゲン受容体モジュレーター市場の予測：規模と成長、2024年～2029年、2034年
• 世界のエストロゲン受容体モジュレーター：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のエストロゲン受容体モジュレーター市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 選択的エストロゲン受容体モジュレーター
• 非選択的エストロゲン受容体モジュレーター
• 選択的エストロゲン受容体ダウンレギュレーター（SERD）
• 世界のエストロゲン受容体モジュレーター市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 注射
• 局所
• 世界のエストロゲン受容体モジュレーター市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 乳がんの治療
• 骨粗鬆症の治療
• 不妊治療
• ホルモン補充療法（HRT）
• 世界のエストロゲン受容体モジュレーター市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のエストロゲン受容体モジュレーター市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界のエストロゲン受容体モジュレーター市場、選択的エストロゲン受容体モジュレーターの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• タモキシフェン
• ラロキシフェン
• トレミフェン
• バゼドキシフェン
• ラソフォキシフェン
• 世界のエストロゲン受容体モジュレーター市場、非選択的エストロゲン受容体モジュレーターの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• クロミフェン
• ジエチルスチルベストロール（DES）
• その他の非選択的モジュレーター
• 世界のエストロゲン受容体モジュレーター市場、選択的エストロゲン受容体ダウンレギュレーター（SERD）の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• フルベストラント
• エラセストラント
• OP-1250（治験薬）
• その他の口腔SERD

第7章 地域別・国別分析

• 世界のエストロゲン受容体モジュレーター市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のエストロゲン受容体モジュレーター市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エストロゲン受容体モジュレーター市場：競合情勢
• エストロゲン受容体モジュレーター市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi SA
• AstraZeneca PLC
• Novartis AG
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Aurobindo Pharma
• Alkem Laboratories Ltd.
• Atossa Therapeutics
• Ligand Pharmaceuticals
• Panacea Biotec
• Sermonix Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エストロゲン受容体モジュレーター市場2029年：新たな機会を提供する国
• エストロゲン受容体モジュレーター市場2029年：新たな機会を提供するセグメント
• エストロゲン受容体モジュレーター市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Estrogen receptor modulators are drugs that attach to estrogen receptors and either mimic estrogen's effects (agonists) or inhibit estrogen activity (antagonists), depending on the specific tissue targeted. This selective action enables their use in treating various hormone-related conditions such as breast cancer, osteoporosis, and menopausal symptoms, providing estrogen's benefits in certain tissues while reducing associated risks in others.

The primary types of estrogen receptor modulators include selective estrogen receptor modulators (SERMs), non-selective estrogen receptor modulators, and selective estrogen receptor down regulators (SERDs). SERMs are compounds that bind to estrogen receptors across different tissues, acting as either agonists or antagonists based on the tissue involved. They can be administered orally, by injection, or topically, and are used in treatments for breast cancer, osteoporosis, infertility, and hormone replacement therapy (HRT). These modulators are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as home care providers, specialty centers, and others.

The estrogen receptor modulators market research report is one of a series of new reports from The Business Research Company that provides estrogen receptor modulators market statistics, including estrogen receptor modulators industry global market size, regional shares, competitors with an estrogen receptor modulators market share, detailed estrogen receptor modulators market segments, market trends and opportunities, and any further data you may need to thrive in the estrogen receptor modulators industry. This estrogen receptor modulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The estrogen receptor modulators market size has grown strongly in recent years. It will grow from $15.73 billion in 2024 to $17.12 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the rising demand for targeted cancer therapies, increased research on selective estrogen receptor modulators (SERMs), a growing number of clinical trials for estrogen-related conditions, and expanding uses in male health disorders.

The estrogen receptor modulators market size is expected to see strong growth in the next few years. It will grow to $23.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth anticipated in the forecast period can be attributed to the expanding pipeline of next-generation SERMs, increased investment in oncology research and development, rising prevalence of hormone-sensitive cancers, broader adoption in personalized medicine, and the expected approval of novel estrogen receptor modulators. Key trends during this period include advancements in selective estrogen receptor degraders (SERDs), development of tissue-selective modulators, innovations in combination therapy approaches, progress in biomarker-based drug targeting, and the creation of oral SERMs with enhanced safety profiles.

The increasing prevalence of breast cancer is expected to drive the growth of the estrogen receptor modulators market in the future. Breast cancer is a condition where abnormal cells in the breast grow uncontrollably, forming tumors that can invade surrounding tissues or spread to other areas of the body. The rise in breast cancer cases is linked to more women delaying childbirth, which alters hormone levels and increases lifetime estrogen exposure, thereby elevating cancer risk. Estrogen receptor modulators play a key role in managing breast cancer by blocking or modifying estrogen's effects on cancer cells, slowing their growth, and reducing the risk of disease progression or recurrence. For example, in February 2025, the United Nations, a US-based intergovernmental organization, reported that in 2022, breast cancer accounted for around 2.3 million new cases and 670,000 deaths worldwide. By 2050, global estimates predict a 38% increase in new cases and a 68% rise in annual deaths, underscoring the growing impact of the disease. Hence, the rising prevalence of breast cancer is propelling the estrogen receptor modulators market forward.

Leading companies in the estrogen receptor modulators market are concentrating on developing innovative treatments, such as estrogen-based menopause hormone therapy, to effectively alleviate menopausal symptoms like hot flashes while minimizing risks associated with hormone-related cancers and cardiovascular issues. Estrogen-based menopause hormone therapy involves administering estrogen alone or combined with progestin to ease menopause-related symptoms. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology firm, reintroduced DUAVEE (conjugated estrogens/bazedoxifene) with updated packaging. This hormone therapy targets postmenopausal women with a uterus and combines conjugated estrogens with bazedoxifene, a selective estrogen receptor modulator. It offers an alternative to conventional estrogen-progestin treatments by lowering the risk of uterine lining thickening. DUAVEE is administered once daily as an oral tablet and is advised for the shortest period necessary to manage symptoms. Common side effects include muscle spasms, nausea, and stomach discomfort.

In April 2024, Atossa Therapeutics, a US-based clinical-stage biopharmaceutical company specializing in selective estrogen receptor modulators (SERMs) for various breast cancer treatments, partnered with Weill Cornell Medicine to explore the potential synergy between antibody-drug conjugates (ADCs) and (Z)-endoxifen. This collaboration aims to assess and confirm the effectiveness of combining (Z)-endoxifen with ADCs to develop improved combination therapies for advanced and metastatic breast cancer. Weill Cornell Medicine, a US-based academic medical institution, is recognized for its leading research in oncology and other therapeutic fields.

Major players in the estrogen receptor modulators market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Aurobindo Pharma, Alkem Laboratories Ltd., Atossa Therapeutics, Ligand Pharmaceuticals, Panacea Biotec, Sermonix Pharmaceuticals Inc., MSN Laboratories, Deus Medical.

North America was the largest region in the estrogen receptor modulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in estrogen receptor modulators report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the estrogen receptor modulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The estrogen receptor modulators market consists of sales of products, including selective estrogen receptor modulators (SERMs), estrogen receptor antagonists, estrogen receptor agonists, and combination hormonal therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Estrogen Receptor Modulators Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on estrogen receptor modulators market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for estrogen receptor modulators ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The estrogen receptor modulators market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Select Estrogen Receptor Modulators; Non-Selective Estrogen Receptor Modulators; Selective Estrogen Receptor Downregulators (SERDs)
• 2) By Route Of Administration: Oral; Injectable; Topical
• 3) By Application: Breast Cancer Treatment; Osteoporosis Treatment; Infertility Treatment; Hormone Replacement Therapy (HRT)
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-Users: Homecare; Speciality Centres; Other End Users
• Subsegments:
• 1) By Select Estrogen Receptor Modulators: Tamoxifen; Raloxifene; Toremifene; Bazedoxifene; Lasofoxifene
• 2) By Non-Selective Estrogen Receptor Modulators: Clomiphene; Diethylstilbestrol (DES); Other Non-Selective Modulators
• 3) By Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant; Elacestrant; OP-1250 (Investigational); Other Oral SERDs
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Estrogen Receptor Modulators Market Characteristics

3. Estrogen Receptor Modulators Market Trends And Strategies

4. Estrogen Receptor Modulators Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Estrogen Receptor Modulators Growth Analysis And Strategic Analysis Framework

• 5.1. Global Estrogen Receptor Modulators PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Estrogen Receptor Modulators Market Growth Rate Analysis
• 5.4. Global Estrogen Receptor Modulators Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Estrogen Receptor Modulators Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Estrogen Receptor Modulators Total Addressable Market (TAM)

6. Estrogen Receptor Modulators Market Segmentation

• 6.1. Global Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Select Estrogen Receptor Modulators
• Non-Selective Estrogen Receptor Modulators
• Selective Estrogen Receptor Downregulators (SERDs)
• 6.2. Global Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.3. Global Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer Treatment
• Osteoporosis Treatment
• Infertility Treatment
• Hormone Replacement Therapy (HRT)
• 6.4. Global Estrogen Receptor Modulators Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Estrogen Receptor Modulators Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End Users
• 6.6. Global Estrogen Receptor Modulators Market, Sub-Segmentation Of Select Estrogen Receptor Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tamoxifen
• Raloxifene
• Toremifene
• Bazedoxifene
• Lasofoxifene
• 6.7. Global Estrogen Receptor Modulators Market, Sub-Segmentation Of Non-Selective Estrogen Receptor Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clomiphene
• Diethylstilbestrol (DES)
• Other Non-Selective Modulators
• 6.8. Global Estrogen Receptor Modulators Market, Sub-Segmentation Of Selective Estrogen Receptor Downregulators (SERDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fulvestrant
• Elacestrant
• OP-1250 (Investigational)
• Other Oral SERDs

7. Estrogen Receptor Modulators Market Regional And Country Analysis

• 7.1. Global Estrogen Receptor Modulators Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Estrogen Receptor Modulators Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Estrogen Receptor Modulators Market

• 8.1. Asia-Pacific Estrogen Receptor Modulators Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Estrogen Receptor Modulators Market

• 9.1. China Estrogen Receptor Modulators Market Overview
• 9.2. China Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Estrogen Receptor Modulators Market

• 10.1. India Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Estrogen Receptor Modulators Market

• 11.1. Japan Estrogen Receptor Modulators Market Overview
• 11.2. Japan Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Estrogen Receptor Modulators Market

• 12.1. Australia Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Estrogen Receptor Modulators Market

• 13.1. Indonesia Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Estrogen Receptor Modulators Market

• 14.1. South Korea Estrogen Receptor Modulators Market Overview
• 14.2. South Korea Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Estrogen Receptor Modulators Market

• 15.1. Western Europe Estrogen Receptor Modulators Market Overview
• 15.2. Western Europe Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Estrogen Receptor Modulators Market

• 16.1. UK Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Estrogen Receptor Modulators Market

• 17.1. Germany Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Estrogen Receptor Modulators Market

• 18.1. France Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Estrogen Receptor Modulators Market

• 19.1. Italy Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Estrogen Receptor Modulators Market

• 20.1. Spain Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Estrogen Receptor Modulators Market

• 21.1. Eastern Europe Estrogen Receptor Modulators Market Overview
• 21.2. Eastern Europe Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Estrogen Receptor Modulators Market

• 22.1. Russia Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Estrogen Receptor Modulators Market

• 23.1. North America Estrogen Receptor Modulators Market Overview
• 23.2. North America Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Estrogen Receptor Modulators Market

• 24.1. USA Estrogen Receptor Modulators Market Overview
• 24.2. USA Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Estrogen Receptor Modulators Market

• 25.1. Canada Estrogen Receptor Modulators Market Overview
• 25.2. Canada Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Estrogen Receptor Modulators Market

• 26.1. South America Estrogen Receptor Modulators Market Overview
• 26.2. South America Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Estrogen Receptor Modulators Market

• 27.1. Brazil Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Estrogen Receptor Modulators Market

• 28.1. Middle East Estrogen Receptor Modulators Market Overview
• 28.2. Middle East Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Estrogen Receptor Modulators Market

• 29.1. Africa Estrogen Receptor Modulators Market Overview
• 29.2. Africa Estrogen Receptor Modulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Estrogen Receptor Modulators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Estrogen Receptor Modulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Estrogen Receptor Modulators Market Competitive Landscape And Company Profiles

• 30.1. Estrogen Receptor Modulators Market Competitive Landscape
• 30.2. Estrogen Receptor Modulators Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Estrogen Receptor Modulators Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi SA
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. Eli Lilly and Company
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Apotex Inc
• 31.9. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• 31.10. Aurobindo Pharma
• 31.11. Alkem Laboratories Ltd.
• 31.12. Atossa Therapeutics
• 31.13. Ligand Pharmaceuticals
• 31.14. Panacea Biotec
• 31.15. Sermonix Pharmaceuticals Inc.

32. Global Estrogen Receptor Modulators Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Estrogen Receptor Modulators Market

34. Recent Developments In The Estrogen Receptor Modulators Market

35. Estrogen Receptor Modulators Market High Potential Countries, Segments and Strategies

• 35.1 Estrogen Receptor Modulators Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Estrogen Receptor Modulators Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Estrogen Receptor Modulators Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer